ProMedica Toledo Hospital is a 794-bed non-profit hospital in Toledo, Ohio operated by ProMedica. The hospital is a Level I trauma center and the largest acute care hospital in the Toledo metropolitan area with at least 4,800 health care professionals, including more than 1,000 specialty and primary care physicians, making it the region's largest employer.The hospital's Toledo campus includes ProMedica Russell J. Ebeid Children's Hospital, a Level II pediatric trauma center with 151 beds, including a 72-bed newborn intensive care unit.Divisions of ProMedica Toledo Hospital include ProMedica Flower Hospital in Sylvania and ProMedica Wildwood Orthopaedic and Spine Hospital in Sylvania Township.In 2015, the University of Toledo entered into a 50-year agreement with ProMedica to affiliate the school's University of Toledo College of Medicine and Life Sciences with the hospital.
Upadacitinib (UPA) and risankizumab (RSK) are alternatives for Crohn’s disease (CD) patients refractory to conventional therapies or biologics, although their optimal positioning is unclear. to compare the durability and effectiveness of UPA and RSK after biologic failure in CD; to identify risk factors for relapse and for therapy discontinuation; and to explore safety profile of UPA and RSK in this scenario. Adult patients from the prospectively-maintained ENEIDA registry of GETECCU who received UPA or RSK as second- (after 1 anti-TNF) or third-line (after 2 anti-TNFs, after 1 anti-TNF+vedolizumab, or after 1 anti-TNF+ustekinumab) with ≥12 weeks of follow-up, were included. Clinical remission was defined as Harvey-Bradshaw Index (HBI) ≤ 4, and clinical response as a decrease in HBI > 3 points. Biologic remission was considered as faecal calprotectin (FC) ≤ 250 µg/g, and biologic response as a reduction of ≥ 50% in FC levels. Endoscopic activity was graded as quiescent (remission), mild, moderate or severe (as endoscopist’s criteria); and radiologic activity as absence/presence according to radiologist. Outcomes were evaluated at 12, 24, and 48 weeks. Treatment durability was analysed using Kaplan-Meier curves, and factors for therapy discontinuation and relapse were identified by Cox regression. All adverse events (AEs) were recorded. A total of 562 patients from 39 centers were included [UPA: n = 242 (43%), RSK: n = 320 (57%)] (Table 1). In second-line, 12 and 24-week durability was 70%/59% for UPA and 72%/72% for RSK; in third-line, 61%/40% for UPA, and 80%/76% for RSK (p < 0.05). Outcomes were included in Table 2. In second-line, predictive factors for therapy discontinuation were stricturing-fistulising behaviour (Hazard Ratio [HR]=1.9, 95% confidence interval [CI]=1.1-3.3), and UPA vs. RSK treatment (HR = 1.8, 95%CI=1.1-3.1). In third-line, UPA treatment was associated with treatment discontinuation (HR = 2.4, 95%CI=1.5-4). The severity of CD at baseline was associated with relapse in second- (HR = 7.1, 95%CI=3.9-12.7) and in third-line (HR = 5.4, 95%CI=3.4-8.7). AEs were reported in 64 (28%) UPA- and 28 (10%) RSK- treated patients (p < 0.05), most commonly acne for UPA, while infections predominated with RSK. Treatment was maintained in 81% of UPA and 91% of RSK patients with AEs (p < 0.05). UPA and RSK are effective options after biologic failure in CD patients. Both agents showed high treatment durability with greater persistence observed for RSK in third-line. CD behaviour and UPA treatment (vs. RSK) were predictive factors for therapy discontinuation, while severity of CD at baseline predicted relapse. AEs occurred more frequently with UPA, leading to a higher rate of treatment discontinuation compared with RSK. References: * P. Nos, M. Barreiro-de Acosta and F. Bermejo share senior authorship. Conflict of interest: Rubín De Célix, Cristina: Cristina Rubín de Célix has received education funding from Ferring, Tillotts Pharma, AbbVie, Sandoz, Alfasigma, Lilly, Norgine, MSD, Pfizer, Takeda, and Janssen Granja, Alicia: No conflict of interest Iborra, Marisa: No conflict of interest Garcia Alonso, Francisco Javier: I have acted as a speaker for Abbvie, Lilly and Johnson and Johnson Vela, Milagros: No conflict of interest de Castro, Luisa: No conflict of interest García-Sola, Claudia: No conflict of interest Barrero, Sara: I have no conflicts of interest to declare. Varela Trastoy, Pilar: No conflict of interest Robledo Andrés, Pilar: No conflict of interest Riestra, Sabino: No conflict of interest Ponferrada Diaz, Angel: financial support for travelling and educational activities from Johnsson and Johnsson, AbbVie, Takeda, Alfasigma, Lilly, Faes Farma and Ferring. Ceballos Santos, Daniel: None Camps, Blau: No conflict of interest Gisbert, Javier: Grant: MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos/Alfasigma, Lilly, Sanofi, STADA, Teva, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine, Italfarmaco, and Vifor Pharma. Personal Fees: MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos/Alfasigma, Lilly, Sanofi, STADA, Teva, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine, Italfarmaco, and Vifor Pharma. Other: MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos/Alfasigma, Lilly, Sanofi, STADA, Teva, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine, Italfarmaco, and Vifor Pharma. García, María José: Other: MJ García has received financial support for travelling and educational activities from Janssen, Pfizer, Abbvie, Takeda and Ferring. Diz-Lois Palomares, Mª Teresa: No conflict of interest Moralejo Lozano, Óscar: I have received educational funding from Abbvie, Johnson & Johnson, Takeda, Kern Pharma, Alfasigma, Pfizer, Lilly, Sandoz, Dr. Falk Pharma, Ferring, and Tillotts. I have also served as a speaker for Abbvie, Takeda, Alfasigma, and Lilly. Rafael de La Cruz, David: No conflict of interest López, Eider: No conflict of interest Martinez Pascual, Cristina: No conflict of interest Izquierdo, Sandra: None. Iglesias Flores, Eva: has served as a speaker, consultant and advisory member for or has received research funding from AbbVie, Janssen, Takeda, Gillead, Celgene, Pfizer, Lilly, Ferring, Faes Farma, Dr. Falk Pharma, Chiesi, and Adacyte, Ferreiro Iglesias, Rocio: RF-I has served as a speaker, or has received research or education funding from AbbVie, Takeda, MSD, Pfizer, Janssen, Adacyte, Ferring, Casen Recordati, Palex, Tillotts Pharma, Dr. Falk, Chiesi, Faes Farma, Alphasigma. Argüelles-Arias, Federico: No conflict of interest Martin, Daniel: I have served as speaker for and received consulting fees from Abbvie, Takeda, Jansen, Ferring, Tillots, Dr. Falk Pharma, Faes Pharma an Persan Ruiz Ramírez, María Ángeles: No conflict of interest Vega Villaamil, Pablo: None Trapero Martinez, Ana María: No conflict of interest Roig Ramos, Cristina: CR has received support for conference attendance and education funding from Kern Pharma, Ferring, Alfasigma, Faes Farma, Pfizer and Takeda. Madero Velázquez, Lucía: None Mañosa Ciria, Miriam: Personal Fees: Abbvie, FAES Pharma, Ferring, Jannsen, MSD, Pfizer, Tillots and Lilly Brunet, Eduard: I have served as a speaker and consultant for Janssen and Chiesi, Kern, Takeda and Alfasigma. Zabana, Yamile: Personal Fees: AbbVie, Adacyte Therapeutics, Alfa-Sigma, Amgen, Boehringer Ingelheim, Dr Falk Pharma, FAES Pharma, Fresenius Kabi, Ferring, Galapagos, Janssen-J & J, Kern Pharma, Lilly, MSD, Pfizer, Sanofi, Sandoz, Takeda, Tillots Pharma Non-financial Support: Shire, Otsuka, Almirall Pajares Villarroya, Ramón: No conflict of interest Altadill, Ariadna: No conflict of interest Domènech Moral, Eugeni: Personal Fees: I have served as a speaker, or has received research or education funding or advisory fees from AbbVie, Adacyte Therapeutics, Biogen, Celltrion, Gilead, Janssen, Kern Pharma, MSD, Pfizer, Roche, Samsung, Takeda, Tillots. Other: I have served as a speaker, or has received research or education funding or advisory fees from AbbVie, Adacyte Therapeutics, Alfasigma/Galapagos Biogen, Celltrion, Ferring, Gilead, GoodGut, Imidomics, Janssen, Kern Pharma, Lilly, MSD, Pfizer, Roche, Takeda, Tillots. Nos Mateu, Pilar: No conflict of interest Barreiro-de Acosta, Manuel: MBA has been speaker, consultant and advisory member for or has received research funding from MSD, AbbVie, Janssen, Kern Pharma, Celltrion, Takeda, Alphasigma, Lilly, Pfizer, Sandoz, Biocon, Abivax, Fresenius, Faes Farma, Ferring, Tillots, Chiesi, Adacyte, Diasorin, Oncostellae and SunRock. Bermejo San Jose, Fernando: No conflict of interest
AIMS:To evaluate the effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction (HFrEF) following recent decompensation in routine clinical practice in Spain. METHODS:VERISEC is a prospective, multicentre registry of 835 consecutive patients initiating vericiguat at 41 centres in Spain. Functional class, biochemical markers, ventricular function, and clinical events were analysed during a 1-year follow-up. RESULTS:Patients (age 71.3 years [SD: 11.2], 78.9% male) received highly optimized baseline therapy: 91.5% SGLT2i, 90.7% beta-blockers, 85.4% RAASi, and 79.8% MRAs. Quadruple therapy remained stable (61.7% baseline to 63.0% at 12 months; P = .526). At 1-year follow-up, significant improvements were observed. NT-proBNP decreased from 3532.0 (IQR: 1689.3-6974.5) to 2291.5 pg/ml (IQR: 1063.0-5076.3; P < .001) and LVEF increased from 30.3% (SD: 7.6) to 35.4% (SD: 11.1; P < .001). NYHA class improved, with class II patients increasing from 55.6% to 62.2% (P < .001). Mean HF decompensations requiring intravenous diuretics decreased from 1.34 (SD: 1.1) in the preceding year to 0.65 (SD: 1.3) during follow-up. Non-HF cardiovascular hospitalizations decreased from 0.98 (SD: 1.4) to 0.39 (SD: 1.0). Vericiguat was discontinued in 13.4% of patients, primarily due to symptomatic hypotension (49.4%). Higher baseline NT-proBNP (per 1000-pg/ml increase) independently predicted discontinuation (OR: 1.06; 95% CI: 1.03-1.08; P < .001). CONCLUSIONS:Vericiguat added to optimized quadruple therapy was associated with reverse remodelling, reduced NT-proBNP, improved functional class, and a numerical reduction in HF-related events in real-world HFrEF patients. These findings confirm the clinical utility and safety of vericiguat in routine practice.
Background Mitral valve transcatheter edge‐to‐edge repair can be more challenging in noncentral regions of the valve and in anterior or bileaflet lesions. We assess effect of implant location and leaflet lesion location on safety and effectiveness of PASCAL Precision system in degenerative mitral regurgitation (MR). Methods Mitral valve transcatheter edge‐to‐edge repair outcomes in patients with degenerative MR treated with PASCAL Precision system (September 2022–October 2024), from the US STS/ACC TVT (Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy) Registry, were analyzed by implant location (A2P2/non‐A2P2) and leaflet lesion location (anterior/posterior/bileaflet). Procedural, clinical, and echocardiographic outcomes to 30 days were assessed. Results At 30 days, both A2P2 (n=1526) and non‐A2P2 (n=299) groups had low event rates (cardiovascular mortality: 1.1% versus 1.0%, mitral valve reintervention: 0.4% versus 0.0% and single leaflet device attachment: 0.5% versus 0.3%; all P>0.05) and demonstrated significant MR reduction (P<0.001 versus baseline) with no significant difference between groups (P=0.750) (MR ≤2+: 93.4% versus 95.4%; MR ≤1+: 72.0% versus 73.3%). Kansas City Cardiomyopathy Questionnaire Overall Summary scores improved significantly in both groups (∆19.3, ∆17.7 points; P=0.741). The anterior (n=250), posterior (n=902), and bileaflet (n=192) disease groups also had low event rates (cardiovascular mortality: 0.4%, 1.1%, 0.0%; mitral valve reintervention: 0.8%, 0.1%, 0.5%; and single leaflet device attachment: 0.8%, 0.2%, 0.5%; all P>0.05), and demonstrated significant MR reduction (P<0.001 versus baseline) with no significant difference across groups (P=0.459) (MR ≤2+: 94.1%, 93.1%, and 94.5%; MR ≤1+: 79.0%, 69.2%, and 72.4%). All groups experienced significant improvement in Kansas City Cardiomyopathy Questionnaire Overall Summary scores (∆21.4, ∆18.8, ∆12.0 points; P=0.087). Conclusion In real‐world patients with degenerative mitral regurgitation, treatment with the PASCAL Precision system was associated with favorable safety and effectiveness at 30 days, regardless of implant location or leaflet lesion location.
Implant fracture is a rare but devastating complication of total hip arthroplasty (THA). We present the case of a patient with a history of prior acetabular fracture who underwent conversion to a dual mobility (DM) THA and subsequently fractured at the neck of the femoral component 7 years after surgery. At revision, both the femoral and acetabular components were noted to be clinically retroverted, suggesting chronic anterior impingement as the cause of the catastrophic failure.